277 related articles for article (PubMed ID: 37615838)
1. Topical Treatment of Melanoma In Situ, Lentigo Maligna, and Lentigo Maligna Melanoma with Imiquimod Cream: A Systematic Review of the Literature.
Vaienti S; Calzari P; Nazzaro G
Dermatol Ther (Heidelb); 2023 Oct; 13(10):2187-2215. PubMed ID: 37615838
[TBL] [Abstract][Full Text] [Related]
2. Interventions for melanoma in situ, including lentigo maligna.
Tzellos T; Kyrgidis A; Mocellin S; Chan AW; Pilati P; Apalla Z
Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010308. PubMed ID: 25526608
[TBL] [Abstract][Full Text] [Related]
3. A systematic review on the role of imiquimod in lentigo maligna and lentigo maligna melanoma: need for standardization of treatment schedule and outcome measures.
Tio D; van der Woude J; Prinsen CAC; Jansma EP; Hoekzema R; van Montfrans C
J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):616-624. PubMed ID: 27987308
[TBL] [Abstract][Full Text] [Related]
4. Series of Fourteen Cases of Topical Imiquimod 5% in Lentigo Maligna: Treatment Modalities and Clues for Detecting Recurrences.
Poveda-Montoyo I; Álvarez-Chinchilla P; Schneller-Pavelescu L; Hispán-Ocete P; Bañuls-Roca J
Actas Dermosifiliogr; 2022 Apr; 113(4):T407-T412. PubMed ID: 35623739
[TBL] [Abstract][Full Text] [Related]
5. Series of Fourteen Cases of Topical Imiquimod 5% in Lentigo Maligna: Treatment Modalities and Clues for Detecting Recurrences.
Poveda-Montoyo I; Álvarez-Chinchilla P; Schneller-Pavelescu L; Hispán-Ocete P; Bañuls-Roca J
Actas Dermosifiliogr; 2022 Apr; 113(4):407-412. PubMed ID: 35431054
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of 5% Topical Imiquimod for Lentigo Maligna Treatment.
Tio DCKS; van Montfrans C; Ruijter CGH; Hoekzema R; Bekkenk MW
Acta Derm Venereol; 2019 Sep; 99(10):884-888. PubMed ID: 31233181
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. Imiquimod 5% cream as primary or adjuvant therapy for melanoma in situ, lentigo maligna type.
Swetter SM; Chen FW; Kim DD; Egbert BM
J Am Acad Dermatol; 2015 Jun; 72(6):1047-53. PubMed ID: 25791801
[TBL] [Abstract][Full Text] [Related]
9. Treatment of periocular lentigo maligna with topical 5% Imiquimod: a review.
Neumann I; Patalay R; Kaushik M; Timlin H; Daniel C
Eye (Lond); 2023 Feb; 37(3):408-414. PubMed ID: 35835989
[TBL] [Abstract][Full Text] [Related]
10. Melanoma in situ treated successfully using imiquimod after nonclearance with surgery: review of the literature.
Ellis LZ; Cohen JL; High W; Stewart L
Dermatol Surg; 2012 Jun; 38(6):937-46. PubMed ID: 22338583
[TBL] [Abstract][Full Text] [Related]
11. A quantitative systematic review of the efficacy of imiquimod monotherapy for lentigo maligna and an analysis of factors that affect tumor clearance.
Mora AN; Karia PS; Nguyen BM
J Am Acad Dermatol; 2015 Aug; 73(2):205-12. PubMed ID: 26088690
[TBL] [Abstract][Full Text] [Related]
12. Topical imiquimod for periocular lentigo maligna.
Demirci H; Shields CL; Bianciotto CG; Shields JA
Ophthalmology; 2010 Dec; 117(12):2424-9. PubMed ID: 20591492
[TBL] [Abstract][Full Text] [Related]
13. Topical imiquimod immunotherapy in the management of lentigo maligna.
Powell AM; Russell-Jones R; Barlow RJ
Clin Exp Dermatol; 2004 Jan; 29(1):15-21. PubMed ID: 14723712
[TBL] [Abstract][Full Text] [Related]
14. Clinical and histologic features associated with lentigo maligna clearance after imiquimod treatment.
Kwak R; Joyce C; Werchniak AE; Lin JY; Tsibris HC
J Dermatolog Treat; 2022 Jun; 33(4):1995-1999. PubMed ID: 34315342
[TBL] [Abstract][Full Text] [Related]
15. Immunocryosurgery as monotherapy for lentigo maligna or combined with surgical excision for lentigo maligna melanoma.
Matas-Nadal C; Sòria X; García-de-la-Fuente MR; Huerva V; Ortega E; Vilardell F; Gatius S; Casanova JM; Martí RM
J Dermatol; 2018 May; 45(5):564-570. PubMed ID: 29430695
[TBL] [Abstract][Full Text] [Related]
16. [Lentigo maligna treated with 5% imiquimod cream].
Martín T; Ojeda A; Martínez S; Vera A
Actas Dermosifiliogr; 2005 Dec; 96(10):700-2. PubMed ID: 16476324
[TBL] [Abstract][Full Text] [Related]
17. Treatment of lentigo maligna with topical imiquimod.
Naylor MF; Crowson N; Kuwahara R; Teague K; Garcia C; Mackinnis C; Haque R; Odom C; Jankey C; Cornelison RL
Br J Dermatol; 2003 Nov; 149 Suppl 66():66-70. PubMed ID: 14616356
[TBL] [Abstract][Full Text] [Related]
18. Topical Imiquimod for Lentigo Maligna: Survival Analysis of 103 Cases With 17 Years Follow-up.
Chambers M; Swetter SM; Baker C; Saunders E; Chapman MS
J Drugs Dermatol; 2021 Mar; 20(3):346-348. PubMed ID: 33683087
[TBL] [Abstract][Full Text] [Related]
19. Treatment of lentigo maligna with imiquimod 5% cream.
Hopson B; Richey D; Sajben FP
J Drugs Dermatol; 2007 Oct; 6(10):1037-40. PubMed ID: 17966182
[TBL] [Abstract][Full Text] [Related]
20. Topical Imiquimod Treatment of Lentigo Maligna.
Ventura F; Rocha J; Fernandes JC; Pardal F; Brito C
Case Rep Dermatol; 2009 Oct; 1(1):78-81. PubMed ID: 20652120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
